Fresh analysis indicates that people who discontinue popular slimming jabs like Mounjaro or Wegovy tend to recover shed pounds at a significantly accelerated pace than those who halt traditional lifestyle programs.
Published data in a major medical journal points out that while overweight individuals often shed substantial amounts of their body weight while undergoing treatment, the weight comes back at an average rate of nearly a kilo each month upon discontinuation.
"Users using such drugs should be aware of the risk of quick weight regain when the therapy is stopped," warns lead investigator Dr. Susan Jebb.
This pace of recovery implies a reversion to pre-treatment mass in about one and a half years.
Comparing Approaches
The research, which reviewed dozens of trials involving thousands of patients, compared the results of GLP-1 agonists with older methods.
The team point out that individuals who shed pounds through diet and exercise generally have a more gradual creep back—perhaps 100 grams monthly—once they finish.
Understanding the Fast Rebound
Nutrition scientists propose the mechanism of the jabs explains the heightened rebound.
The injections mimic a body's own chemical called GLP-1, which controls hunger.
"Long-term administration of the hormone levels several times higher than normal might result in the system to produce less of its own natural GLP-1, and may also diminish responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' leads to hunger is no longer kept in check, making binge eating a significant risk."
A Lifelong Disease?
The NHS advise the injections for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Many experts contend that, considering the significant potential of weight regain, the therapy might need to be long-term.
This opinion is supported by pharmaceutical companies, who state that the findings "underscore the long-term character of excess weight," akin to managing conditions like high blood pressure.
Patient Accounts
People who have discontinued the jabs report a intense return of cravings.
"It felt as if something that goes on and you become starving," described a patient.
This challenge is compounded if users have not adopted sustainable lifestyle or habit modifications during therapy.
Widespread Use
Figures suggest that a significant number of people in the UK have tried these injections in the last 12 months, with interest continuing to grow.
- Adoption is more common among women compared to males.
- The middle-aged demographic shows the greatest usage rates.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, researchers stress that while GLP-1 drugs are powerful tools for shedding pounds, they are not a magic solution and lasting health benefits hinges on combined lifestyle management.
